2 Result(s)
within
Nicole G Chau
Health Promotion and Disease Prevention
Oncology
-
Article
Open AccessAprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature
Aprepitant is an FDA-approved medication for chemotherapy-induced nausea and vomiting. It blocks substance P binding to neurokinin-1; substance P has been implicated in itch pathways both as a local and global...
-
Article
Open AccessEarly mortality and overall survival in oncology phase I trial participants: can we improve patient selection?
Patient selection for phase I trials (PIT) in oncology is challenging. A typical inclusion criterion for PIT is 'life expectancy > 3 months', however the 90 day mortality (90DM) and overall survival (OS) of pa...
